Working with TipRanks
Follow Us
Stocks
ETFs
Options
Crypto
Research Tools
Calendars
Calculators
Education
About Us
Working with TipRanks
Follow Us
Neurocrine (NBIX)
NASDAQ:NBIX
Neurocrine (NBIX) Stock Price & Analysis
1,108 Followers
NBIX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$89.04 - $126.30
Previous Close$117.12
Volume1.03M
Average Volume (3M)686.44K
Market Cap
$11.46B
Enterprise Value$10.62B
Total Cash (Recent Filing)$1.10B
Total Debt (Recent Filing)$255.80M
Price to Earnings (P/E)62.7
Beta0.44
Next Earnings
Feb 06, 2024EPS Estimate
$1.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.87
Shares Outstanding98,251,923
10 Day Avg. Volume638,774
30 Day Avg. Volume686,439
Standard Deviation0.10
R-Squared0.04
Alpha0.00237
Financial Highlights & Ratios
Price to Book (P/B)5.67
Price to Sales (P/S)7.70
Price to Cash Flow (P/CF)13.20
P/FCF Ratio13.60
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.95
Enterprise Value/Gross Profit7.24
Enterprise Value/Ebitda39.49
Forecast
1Y Price Target
$132.84Price Target Upside13.42% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering19
Neurocrine News
Ownership Overview
1.57% Insiders
24.46% Mutual Funds
51.92% Other Institutional Investors
22.05% Public Companies and
Individual Investors
NBIX FAQ
What was Neurocrine’s price range in the past 12 months?
Neurocrine lowest stock price was $89.04 and its highest was $126.30 in the past 12 months.
What is Neurocrine’s market cap?
Currently, no data Available
When is Neurocrine’s upcoming earnings report date?
Neurocrine’s upcoming earnings report date is Feb 06, 2024 which is in 66 days.
How were Neurocrine’s earnings last quarter?
Neurocrine released its earnings results on Oct 31, 2023. The company reported $0.82 earnings per share for the quarter, missing the consensus estimate of $1.039 by -$0.219.
Is Neurocrine overvalued?
According to Wall Street analysts Neurocrine’s price is currently Undervalued.
Does Neurocrine pay dividends?
Neurocrine does not currently pay dividends.
What is Neurocrine’s EPS estimate?
Neurocrine’s EPS estimate is $1.22.
How many shares outstanding does Neurocrine have?
Neurocrine has 98,251,920 shares outstanding.
What happened to Neurocrine’s price movement after its last earnings report?
Neurocrine reported an EPS of $0.82 in its last earnings report, missing expectations of $1.039. Following the earnings report the stock price went up 3.556%.
Which hedge fund is a major shareholder of Neurocrine?
Among the largest hedge funds holding Neurocrine’s share is Deerfield Management Company, LP. It holds Neurocrine’s shares valued at 136M.
---
Neurocrine Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$132.84 (13.42% Upside)
$132.84 (13.42% Upside)
Blogger Sentiment
Bullish
NBIX Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 40.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 1.8%
Last 30 Days ▼ 0.3%
Last 30 Days ▼ 0.3%
News Sentiment
Positive
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-7.27%
12-Months-Change
Fundamentals
Return on Equity
10.77%
Trailing 12-Months
Asset Growth
32.88%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Neurocrine
Neurocrine Biosciences, Inc. operates as a product based bio-pharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The company product includes INGREZZA. Neurocrine Biosciences was founded by Kevin C. Gorman and Wylie W. Vale on January 1992 and is headquartered in San Diego, CA.
---
Top 5 ETFs holding NBIX
Vanguard Total Stock Market ETF
$339.57M
Vanguard Russell 1000 Growth ETF
$9.02M
Vanguard Russell 1000 ETF
$1.52M
Vanguard Russell 3000 ETF
$699.81K
SPDR S&P 1500 Value Tilt ETF
$25.77K
Up to five ETFs with an Outperform Smart Score that hold NBIX. The ETFs are listed according to market value of NBIX within the ETF
---